Abstract: The invention provides Stat3 and Tyk2 targets that have importance for diagnosis of neurodegenerative diseases such as Alzheimer's disease. Stat3 and Tyk2 are also important as targets for drug development for neurodegenerative diseases.
Type:
Grant
Filed:
June 30, 2008
Date of Patent:
September 15, 2015
Assignee:
Biotechnology Research Corporation Limited
Inventors:
Nancy Yuk-Yu Ip, Zhenguo Wu, Jerry Hsueh-Ching Wang, Kit Yu Fu, Jun Wan
Abstract: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.
Type:
Grant
Filed:
September 19, 2009
Date of Patent:
May 12, 2015
Assignee:
Biotechnology Research Corporation
Inventors:
Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu
Abstract: Isolated compounds from adelostemma gracillimum refined fractions and compositions containing the compounds are provided by the present invention. Adelostemma gracillimum refined fractions and the extraction process thereof are also provided by the present invention. The uses of the compounds and the adelostemma gracillimum refined fractions for inhibiting the activities of NMDA receptor or amyloid-beta peptide, for improving memory, and for treating neurodegenerative diseases, neuropathological conditions or epilepsy are further provided by the present invention.
Type:
Application
Filed:
March 18, 2011
Publication date:
March 28, 2013
Applicant:
BIOTECHNOLOGY RESEARCH CORPORATION LIMITED
Abstract: The present invention provides therapeutically active compounds and compositions as NMDA and MC receptor antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA and/or MC receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, methods of enhancing the brain's cognitive functions and methods of treating depression, anxiety and cachexia induced by a chronic disease in mammals and humans.
Type:
Application
Filed:
January 5, 2012
Publication date:
January 10, 2013
Applicant:
Biotechnology Research Corporation Limited
Inventors:
Nancy Yuk-Yu Ip, Fanny Chui-Fun Ip, Yueqing Hu, Wen Cai Ye
Abstract: The invention provides Stat3 and Tyk2 targets that have importance for diagnosis of neurode-generative diseases such as Alzheimer's disease. Stat3 and Tyk2 are also important as targets for drug development for neurodegenerative diseases.
Type:
Application
Filed:
June 30, 2008
Publication date:
August 4, 2011
Applicant:
Biotechnology Research Corporation Limited
Inventors:
Nancy Yuk-Yu Ip, Zhenguo Wu, Jerry Hsueh-Ching Wang, Kit Yu Fu, Jun Wan
Abstract: The present invention provides therapeutically active oxazolidine derivatives and compositions as NMDA antagonists, which are useful in preventing and treating central nervous system disorders by inhibiting over-activation of NMDA receptors. In one aspect, the present invention provides methods of treating and/or preventing neurodegenerative diseases and neuropathological disorders, methods of providing neuroprotection under stress conditions such as a stroke, and methods of enhancing the brain's cognitive functions in mammals and humans. For example, the compounds can prevent glutamate-induced neuro-toxicity by inhibiting the activities of the NMDA receptor in the presence of toxic doses of NMDA. In addition, the compounds can potentiate the calcium current in the presence of low dose of NMDA.
Type:
Application
Filed:
January 16, 2009
Publication date:
June 16, 2011
Applicant:
Biotechnology Research Corporation Limited
Inventors:
Nancy Yuk-Yu Ip, Hua-Jie Zhu, Fanny Chui-Fun Ip
Abstract: Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.
Type:
Grant
Filed:
January 22, 2007
Date of Patent:
October 20, 2009
Assignee:
Biotechnology Research Corporation Ltd.
Inventors:
Nancy Y Ip, Fanny Chui Fun Ip, Yueqing Hu, Yifan Han, Sookja Kim Chung
Abstract: Novel heterodimers of tetrahydroacridines and tetrahydroquinolinones are disclosed. The heterodimers are capable of acting as both acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor antagonists. The heterodimers may be used to improve cognitive defects via treatment or prevention in both humans and non-humans.
Type:
Application
Filed:
January 22, 2007
Publication date:
July 24, 2008
Applicant:
BIOTECHNOLOGY RESEARCH CORPORATION LIMITED
Inventors:
Nancy Y. IP, Fanny Chui Fun IP, Yueqing Hu, Yifan Han, Sookja Kim Chung